Scarica l'app Stockscreener
100.65
6.94%
6.535
Dopo l'orario di chiusura:
100.65
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché MIRM Giù?
Forum
Previsione
Precedente Chiudi:
$94.11
Aprire:
$94.95
Volume 24 ore:
838.97K
Relative Volume:
0.87
Capitalizzazione di mercato:
$6.14B
Reddito:
$569.61M
Utile/perdita netta:
$-23.36M
Rapporto P/E:
-7.3984
EPS:
-13.6043
Flusso di cassa netto:
$54.87M
1 W Prestazione:
-5.00%
1M Prestazione:
-21.56%
6M Prestazione:
+0.18%
1 anno Prestazione:
+68.25%
Intervallo 1D:
$94.25
$101.64
Intervallo di 1 settimana:
$88.88
$107.00
Portata 52W:
$57.79
$130.00
Mirum Pharmaceuticals Inc Stock (MIRM) Company Profile
Nome
Mirum Pharmaceuticals Inc
Settore
Industria
Telefono
650-667-4085
Indirizzo
989 EAST HILLSDALE BOULEVARD, SUITE 300, FOSTER CITY
Compare MIRM vs VRTX, REGN, ARGX, RVMD, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MIRM
Mirum Pharmaceuticals Inc
|
100.65 | 6.96B | 569.61M | -23.36M | 54.87M | -13.60 |
VRTX
Vertex Pharmaceuticals Inc
|
496.07 | 121.57B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
784.36 | 69.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
865.04 | 55.61B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
205.15 | 39.98B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
348.27 | 33.81B | 5.76B | 514.49M | 1.10B | 4.4813 |
Mirum Pharmaceuticals Inc Stock (MIRM) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-02-18 | Iniziato | RBC Capital Mkts | Outperform |
| 2025-09-24 | Iniziato | TD Cowen | Buy |
| 2025-08-11 | Ripresa | Stifel | Buy |
| 2025-05-19 | Ripresa | H.C. Wainwright | Buy |
| 2024-04-17 | Iniziato | Stifel | Buy |
| 2023-12-18 | Reiterato | H.C. Wainwright | Buy |
| 2023-11-20 | Ripresa | JP Morgan | Overweight |
| 2023-11-13 | Iniziato | Morgan Stanley | Overweight |
| 2023-10-24 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-10-17 | Ripresa | Evercore ISI | Outperform |
| 2023-09-20 | Iniziato | JMP Securities | Mkt Outperform |
| 2022-09-01 | Iniziato | Citigroup | Buy |
| 2021-09-20 | Iniziato | JP Morgan | Overweight |
| 2020-08-07 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2020-08-03 | Iniziato | H.C. Wainwright | Buy |
| 2020-07-31 | Iniziato | Piper Sandler | Overweight |
| 2020-06-25 | Iniziato | Robert W. Baird | Outperform |
| 2019-08-12 | Iniziato | Citigroup | Buy |
| 2019-08-12 | Iniziato | Evercore ISI | Outperform |
| 2019-08-12 | Iniziato | Guggenheim | Buy |
| 2019-08-12 | Iniziato | ROTH Capital | Buy |
| 2019-08-12 | Iniziato | Raymond James | Outperform |
Mostra tutto
Mirum Pharmaceuticals Inc Borsa (MIRM) Ultime notizie
Mirum Pharmaceuticals Inc (MIRM) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Mirum Pharmaceuticals Inc (MIRM) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Mirum Pharmaceuticals Inc (MIRM) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Mirum Pharmaceuticals Inc (MIRM) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Mirum Pharmaceuticals Market Sentiment - Benzinga España
Mirum Pharmaceuticals, Inc. Revenue Breakdown – BIVA:MIRM - TradingView
MIRM|Mirum Pharmaceuticals Inc|Price:113.030|Chg%:-1.330 - TradingKey
Mirum Pharmaceuticals, Inc. (MIRM) options chain - Yahoo Finance UK
Stifel reiterates Mirum Pharmaceuticals stock rating after rival trial fails - Investing.com
Stifel reiterates Mirum Pharmaceuticals stock rating after rival trial fails By Investing.com - Investing.com Canada
Mirum Pharmaceuticals Inc (MIRM) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
MIRM Stock Clocks Best Day In 4.5 Months On Liver Disease Trial Data: Retail Eyes Buyout At A Premium - Stocktwits
Mirum Pharmaceuticals, Inc. (MIRM) Stock Analysis: Exploring a 25.62% Potential Upside in the Biotech Arena - DirectorsTalk Interviews
Why (MIRM) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Citizens reiterates Mirum Pharmaceuticals stock rating on revenue outlook By Investing.com - Investing.com Canada
Why is Mirum Pharmaceuticals (MIRM) down 10.1% since last earnings report? - MSN
Arcutis Expands Board of Directors with Appointment of Chris Peetz - GlobeNewswire Inc.
MIRM5806400 Bond Risk Profile - TradingView
US604749AB7 Bond Coupon Profile — Rate & Payments - TradingView
US604749AB7 Bond Profile — Key Metrics - TradingView
US604749AC5 Bond Profile — Key Metrics - TradingView
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Insider Sell Alert: Eric Bjerkholt Sells 5,000 Shares of Mirum P - GuruFocus
Mirum Pharmaceuticals Insider Sold Shares Worth $611,273, According to a Recent SEC Filing - Moomoo
Form 4 Mirum Pharmaceuticals Inc For: 8 July By Investing.com - Investing.com Nigeria
Mirum Pharmaceuticals CEO Christopher Peetz sells $2.4 million in stock By Investing.com - Investing.com South Africa
Mirum Pharmaceuticals Insider Sold Shares Worth $2,445,382, According to a Recent SEC Filing - Moomoo
Mirum Pharmaceuticals CEO Christopher Peetz sells $2.4 million in stock - Investing.com
Mirum Pharmaceuticals CFO Eric Bjerkhot sells $611,273 in stock - Investing.com
Mirum Pharmaceuticals CFO Eric Bjerkhot sells $611,273 in stock By Investing.com - Investing.com India
Mirum Pharmaceuticals (MIRM) CEO sells 20,000 shares after exercising options - Stock Titan
Mirum Pharmaceuticals (MIRM) CFO sells 5,000 shares under 10b5-1 plan - Stock Titan
Mirum Pharmaceuticals outlines its liver disease focus as shares trade on Nasdaq - AD HOC NEWS
RBC Capital Adjusts Mirum Pharmaceuticals Price Target to $148 From $142, Maintains Outperform Rating - marketscreener.com
Christopher Peetz plans 20,000-share sale (NASDAQ: MIRM) - Stock Titan
Eric Bjerkholt reports sale of 5,000 MIRM shares (MIRM) - Stock Titan
Enterprise value to EBIT forward of Mirum Pharmaceuticals, Inc. – NASDAQ:MIRM - TradingView
Mirum Pharmaceuticals: This Liver Disease Juggernaut Just Broadened Its Portfolio - Seeking Alpha
MIRMMirum Pharmaceuticals Inc Latest SEC Filings - Finviz
Insider Sell: Jolanda Howe Sells Shares of Mirum Pharmaceuticals Inc (MIRM) - GuruFocus
Mirum Pharmaceuticals SVP sells $326,520 in common stock By Investing.com - Investing.com South Africa
Form 4 Mirum Pharmaceuticals Inc For: 2 July By Investing.com - Investing.com Canada
Mirum Pharmaceuticals SVP sells $326,520 in common stock - Investing.com
Mirum Pharmaceuticals (MIRM) SVP Howe sells 2,721 shares under 10b5-1 plan - Stock Titan
Mirum Pharmaceuticals stock hits all-time high at 125.41 USD By Investing.com - Investing.com South Africa
Mirum Pharmaceuticals stock hits all-time high at 125.41 USD - Investing.com
J.P. Morgan Maintains Mirum Pharmaceuticals(MIRM.US) With Buy Rating, Raises Target Price to $125 - Moomoo
The Bull Case For Mirum Pharmaceuticals (MIRM) Could Change Following Priority FDA Review Of FOP Drug Zilurgisertib - Yahoo Finance
Form 144 MIRUM PHARMACEUTICALS For: 1 July By Investing.com - Investing.com Canada
Mirum Pharmaceuticals Inc Azioni (MIRM) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.84%
0.86%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):